Viracta Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
License and other revenue
Operating expenses:
Research and development
Purchased and acquired in-process research and development
General and administrative
Total operating expenses
Gain on royalty purchase agreement
Loss from operations
Other income (expense):
Gain on forgiveness of PPP Loan
Interest income
Interest expense
Other expense
Other income
Total other income (expense)
Net loss per share of common stock, basic and diluted
Weighted-average shares used to compute basic and diluted net loss per share
Net loss
Unrealized (loss) and gain on available-for-sale securities
Unrealized gain (loss) on short-term investments
Comprehensive loss
Net loss per share of common stock, basic
Net loss per share of common stock, diluted
Weighted-average shares used to compute basic net loss per share
Weighted-average shares used to compute diluted net loss per share

Comments